Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 313

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 313
---
). Based on the robustness, moving forward the lab could set
a criterion for minimal gDNA requirement to be 0.7ng or 1ng for testing clinical samples. Based on these data, APOE Genotyping
test is ready to be used in DiamiR lab for commercial purposes.

A recent paper published in
Nature Medicine titled “APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease” (Nature
Medicine, 2024, https://doi.org/10.1038/s41591-024-02931-w) demonstrated that APOE4 homozygotes, i.e. people who carry
two copies of this Alzheimer’s risk gene, represent a genetic form of AD, suggesting the need for broader biomarker testing
and “individualized prevention strategies” in clinical trials. A number of companies, for example Alzheon, NextCure, and Switch
Therapeutics are pursuing APOE4 as a target for therapeutic intervention.

For pharma services contract
work, DiamiR may use a 3 party lab for protein biomarker testing. This would free up capacity in its lab for clinical validation
work while generating near-term revenue for DiamiR. DiamiR has identified two potential partner labs for this work and are conducting
its diligence on their capabilities.

Laboratory Information Management Systems

DiamiR’s future clinical
services will be largely dependent on its internally developed Laboratory Information Management System or LIMS, which is its automated
basis of managing operations and storing data and customer information. This LIMS was developed to meet its CLIA/CAP regulatory requirements
and was reviewed as part of its most recent CLIA inspection in 2024, which DiamiR passed. Currently the LIM System is fully operational.

Clinical Research Collaborators

DiamiR currently has ongoing
collaborations with: The Trustees of the University of Pennsylvania, Alzheimer’s Therapeutic Research Institute of University of
Southern California, Brain Health Imaging Institute of Weill Cornell Medicine (BHII), and New York University School of Medicine.
These institutions provide DiamiR with well-characterized plasma samples and associated demographic and clinical data for the analysis.

DiamiR previously collaborated
with The Roskamp Institute Memory Center, Sarasota, FL; Washington University Alzheimer’s Disease Research Center; Center for Neurodegenerative
Disease Research at University of Pennsylvania; Alzheimer’s Disease Cooperative Study (ADCS) Biomarker Core at University of California,
San